BTAI - Company ID 0001720893
The table below shows BioXcel Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $642.00K | $2.27M | $1.38M | $375.00K | - | - |
| Cost of revenue | $164.00K | $2.14M | $1.26M | $20.00K | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $30.25M | $30.43M | $84.33M | $91.24M | $52.71M | $57.99M |
| SG&A |
BioXcel Therapeutics, Inc. reported annual revenue of $642.00K for fiscal year 2025. That is down 71.7% from $2.27M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.49M |
| $34.49M |
| $83.41M |
| $68.76M |
| $54.23M |
| $24.30M |
| Operating income | -$50.46M | -$67.25M | -$171.78M | -$159.65M | -$106.94M | -$82.30M |
| Income tax | $0.00 | $0.00 | $0.00 | - | - | - |
| Net income | -$69.90M | -$59.60M | -$179.05M | -$165.76M | -$106.93M | -$82.17M |
| EPS (diluted) | -$5.73 | -$23.51 | -$98.33 | -$5.92 | -$4.05 | -$3.79 |